Description
Duprost (Dutasteride) 0.5 mg
Duprost (dutasteride) 0.5 mg is a prescription medicine in capsule form. It is used for benign prostatic hyperplasia, a non-cancerous enlargement of the prostate that can contribute to urinary symptoms in men.
Active Ingredient and Medicine Class
The verified active ingredient is dutasteride 0.5 mg. Dutasteride belongs to the 5-alpha-reductase inhibitor class. Medicines in this group reduce the conversion of testosterone to dihydrotestosterone, a hormone involved in prostate growth.
Established Medical Uses
Dutasteride is established for the treatment of moderate to severe symptoms of benign prostatic hyperplasia. Official prescribing information also describes its use to reduce the risk of acute urinary retention and the need for surgery related to BPH in appropriate patients.
It may be used alone or, in some settings, together with an alpha-blocker when clinically appropriate. It is not a treatment for prostate cancer and should not be described as a cancer-prevention medicine.
How It Works
Dutasteride inhibits both type 1 and type 2 5-alpha-reductase enzymes. This lowers dihydrotestosterone levels, which can gradually reduce prostate volume and help relieve lower urinary tract symptoms linked to prostate enlargement. The effect is gradual rather than immediate.
Important Safety Information
Dutasteride is contraindicated in pregnancy because it may harm a male fetus. Women who are pregnant or may become pregnant should not handle leaking capsules. The medicine is also not intended for use in women or children.
Important precautions include the need to consider other causes of urinary symptoms before treatment and to remember that dutasteride lowers prostate-specific antigen values, which can affect interpretation of prostate cancer screening. Caution is advised with potent, chronic CYP3A4 inhibitors, which may increase dutasteride exposure. The product information also notes concerns about blood donation after use and advises attention to sexual and breast-related adverse effects. Recent European safety review actions have also highlighted monitoring for possible mood-related adverse effects, including suicidal ideation, as a precautionary class concern.
Possible Side Effects
Commonly reported adverse effects include reduced libido, erectile dysfunction, ejaculation disorders, and breast-related reactions such as tenderness or enlargement. Some patients may experience dizziness or mood changes.
Serious but less common reactions can include hypersensitivity reactions, angioedema, and breast cancer in men. Any persistent, severe, or unexpected symptoms should be reviewed by a healthcare professional.
Scientific Evidence
Human studies and reviews consistently show that dutasteride improves symptoms of BPH in men with enlarged prostates, reduces prostate size over time, and lowers the risk of acute urinary retention and BPH-related surgery. Evidence also supports its role as a long-term disease-modifying therapy rather than a rapid symptom reliever.
Systematic reviews and meta-analyses have generally found dutasteride to be effective and broadly well tolerated, while also confirming the well-known sexual adverse-effect profile. Research has also examined safety signals around mood effects and prostate cancer outcomes, so current use remains grounded in established BPH indications rather than speculative benefits.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, full prescribing information, or an individual assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / U.S. FDA AVODART (dutasteride) soft gelatin capsules, prescribing information. View official prescribing information
- electronic Medicines Compendium (emc) Dutasteride 0.5 mg soft capsules, Summary of Product Characteristics. View official product information
- Dolder C et al. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia. Annals of Pharmacotherapy, 2006. View scientific article
- Rebello E et al. Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia. Clinical Interventions in Aging, 2012. View scientific article
